Martin E Dowty

List of Publications by Year in Descending Order

42 papers	2,207 citations	22 h-index	46 g-index
46 ext. papers	2,609 ext. citations	4.8 avg, IF	4.05 L-index

#	Paper	IF	Citations
42	Assessment of the Effects of Inhibition or Induction of CYP2C19 and CYP2C9 Enzymes, or Inhibition of OAT3, on the Pharmacokinetics of Abrocitinib and Its Metabolites in Healthy Individuals.. *European Journal of Drug Metabolism and Pharmacokinetics*, **2022**, 1	2.7	1
41	Effects of Hepatic Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites. *Journal of Clinical Pharmacology*, **2021**, 61, 1311-1323	2.9	7
40	Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF-06826647: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study. *Clinical and Translational Science*, **2021**, 14, 671-682	4.9	6
39	Demonstration of In Vitro to In Vivo Translation of a TYK2 Inhibitor That Shows Cross Species Potency Differences. *Scientific Reports*, **2020**, 10, 8974	4.9	4
38	Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug Exposure and Support Dosing Recommendations for Potential Drug-Drug Interactions or in Special Populations: An Example Using Tofacitinib. *Journal of Clinical Pharmacology*, **2020**, 60, 1617-1628	2.9	3
37	Design and optimization of a series of 4-(3-azabicyclo[3.1.0]hexan-3-yl)pyrimidin-2-amines: Dual inhibitors of TYK2 and JAK1. *Bioorganic and Medicinal Chemistry*, **2020**, 28, 115481	3.4	3
36	Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases. *Journal of Medicinal Chemistry*, **2020**, 63, 13561-13577	8.3	19
35	Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition. *Pharmacology Research and Perspectives*, **2019**, 7, e00537	3.1	41
34	The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis. *Journal of Clinical Pharmacology*, **2018**, 58, 434-447	2.9	41
33	Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases. *Journal of Medicinal Chemistry*, **2018**, 61, 1130-1152	8.3	57
32	Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841). *Journal of Medicinal Chemistry*, **2018**, 61, 8597-8612	8.3	54
31	Identification of Cyanamide-Based Janus Kinase 3 (JAK3) Covalent Inhibitors. *Journal of Medicinal Chemistry*, **2018**, 61, 10665-10699	8.3	23
30	LC-MS/MS assay for N-methylnicotinamide in humans, an endogenous probe for renal transporters. *Bioanalysis*, **2018**, 10, 673-689	2.1	5
29	Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans. *Journal of Medicinal Chemistry*, **2017**, 60, 1971-1993	8.3	77
28	Clearance Prediction of Targeted Covalent Inhibitors by In Vitro-In Vivo Extrapolation of Hepatic and Extrahepatic Clearance Mechanisms. *Drug Metabolism and Disposition*, **2017**, 45, 1-7	4	22
27	Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition. *ACS Chemical Biology*, **2016**, 11, 3442-3451	4.9	85
26	Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies. *MAbs*, **2016**, 8, 1064-78	6.6	47

25	The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. *Clinical and Experimental Rheumatology*, **2016**, 34, 318-28	2.2	155
24	Evaluation of the potential interaction between tofacitinib and drugs that undergo renal tubular secretion using metformin, an in vivo marker of renal organic cation transporter 2. *Clinical Pharmacology in Drug Development*, **2014**, 3, 499-507	2.3	7
23	The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans. *Drug Metabolism and Disposition*, **2014**, 42, 759-73	4	142
22	Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis. *Journal of Pharmacology and Experimental Therapeutics*, **2014**, 348, 165-73	4.7	79
21	Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data. *British Journal of Clinical Pharmacology*, **2012**, 74, 109-15	3.8	29
20	Animal Models for Evaluation of Drug-Drug Interaction Potential of Biotherapeutics. *Current Drug Metabolism*, **2012**, 13, 947-950	3.5	2
19	Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). *Journal of Immunology*, **2011**, 186, 4234-43	5.3	466
18	How current understanding of clearance mechanisms and pharmacodynamics of therapeutic proteins can be applied for evaluation of their drug-drug interaction potential. *Drug Metabolism and Disposition*, **2011**, 39, 1779-83	4	22
17	Drug design structural alert: formation of trifluoroacetaldehyde through N-dealkylation is linked to testicular lesions in rat. *International Journal of Toxicology*, **2011**, 30, 546-50	2.4	4
16	ADME **2010**, 145-200		3
15	Discovery of an Oral Potent Selective Inhibitor of Hematopoietic Prostaglandin D Synthase (HPGDS). *ACS Medicinal Chemistry Letters*, **2010**, 1, 59-63	4.3	19
14	Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. *Journal of Inflammation*, **2010**, 7, 41	6.7	327
13	A holistic strategy for characterizing the safety of metabolites through drug discovery and development. *Chemical Research in Toxicology*, **2009**, 22, 1653-62	4	57
12	Discovery of orally bioavailable 1,3,4-trisubstituted 2-oxopiperazine-based melanocortin-4 receptor agonists as potential antiobesity agents. *Journal of Medicinal Chemistry*, **2008**, 51, 6055-66	8.3	18
11	Approach for extrapolating in vitro metabolism data to refine bioconcentration factor estimates. *Chemosphere*, **2008**, 70, 1804-17	8.4	71
10	Small-molecule melanin-concentrating hormone-1 receptor antagonists require brain penetration for inhibition of food intake and reduction in body weight. *Journal of Pharmacology and Experimental Therapeutics*, **2008**, 324, 206-13	4.7	14
9	The efficacy and cardiac evaluation of aminomethyl tetrahydronaphthalene ketopiperazines: a novel class of potent MCH-R1 antagonists. *Bioorganic and Medicinal Chemistry*, **2007**, 15, 2092-105	3.4	8
8	Aminomethyl tetrahydronaphthalene ketopiperazine MCH-R1 antagonists--Increasing selectivity over hERG. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 819-22	2.9	8

7	Novel pyrazolopiperazinone- and pyrrolopiperazinone-based MCH-R1 antagonists. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 657-61	2.9	6
6	Design, synthesis, and evaluation of proline and pyrrolidine based melanocortin receptor agonists. A conformationally restricted dipeptide mimic approach. *Journal of Medicinal Chemistry*, **2006**, 49, 4745-61	8.3	10
5	Design and synthesis of piperazine-based matrix metalloproteinase inhibitors. *Journal of Medicinal Chemistry*, **2000**, 43, 369-80	8.3	87
4	Development of new hydroxamate matrix metalloproteinase inhibitors derived from functionalized 4-aminoprolines. *Journal of Medicinal Chemistry*, **2000**, 43, 4948-63	8.3	68
3	The next generation of MMP inhibitors. Design and synthesis. *Annals of the New York Academy of Sciences*, **1999**, 878, 40-60	6.5	29
2	Design, synthesis, and biological evaluation of matrix metalloproteinase inhibitors derived from a modified proline scaffold. *Journal of Medicinal Chemistry*, **1999**, 42, 5426-36	8.3	49
1	Improved prediction of in vivo peroral absorption from in vitro intestinal permeability using an internal standard to control for intra- and inter-rat variability. *Pharmaceutical Research*, **1997**, 14, 1792-7	4.5	27